criteria of tumor stage V is thought to be valuable only to screen the G1 level (gram level, coincides with clinical and preclinical cancer), but not suitable for screening all clinical cancers (weighing more than a few grams). Thus, the criteria of the G2 level (Fig. 4) was used in the cooperative study with the Mayo Clinic and the National Cancer Institute..

Third, with the introduction of the staging classification model based on the natural history of preclinical and clinical cancer, we can treat cancer from microcancers to the clinical form in a unified manner, because we have a system in which we can investigate cancer by closely relating basic and clinical studies. 1,8,9,20,32
References

1. Kobayashi T. The detection and treatment of microcancer. Am J Acupuncture 1985; 13:137-47.
2. Kobayashi T, Kawakubo T, Ohki M, Suzuki H, Hayashida S, Takeda Y. Usefulness of the tumor marker combination assay for the diagnosis of various kinds of early cancers. Proceedings o f the Ninth Annual Meeting of the Tumor Marker 1989; 5:263-4.
3. Ministry of Health and Welfare. The 5th report of the National Survey of Malignant Neoplasm. Ministry of Health and Welfare, 1990:102-3.
4. Hodges GM, Hicks RM, Spacey GD. Epithelial-stromal interactions in normal and chemical carcinogen-treated adult bladder. Cancer Res 1977; 37:3720-30.
5. Taguchi 0. Role of the stroma in the normal and abnormal development of the urogenital organs. Jpn J Cancer Chemother 1984; 11(3):670-6.
6. Folk J, Watoson K, Inburger D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58-61.
7. Kobayashi T. An effective program for cancer prevention. Am J Acupuncture 1987; 15:215-20.
8. Tanimizu T, Sugimoto K, Hayashi N, Miura M, Kijima C, Jo T, et al. New approach to Chinese herb medicine, inhibition by Chinese herb medicine "Sun Advance" of SV 40-transformation in mouse cells. Proc Symp WAKAN-YAKU 1982; 15:228-33.
9. Sugimoto K, Jo T, Tanimizu T, Hayashi N, Dohgome M, Shibata K, et al. The effects of the antitumor herb medicine "Sun Advance" in mice. Proc Sympo WAKAN-YAKU 1982;15:224-7.
10. Kobayashi T. Combination of immunomodulators according to endogenous tumor necrosis factor induction. Int J Immunotherapy 1987; 3(4):285-92.
11. Fishman WH, Inglis NR, Stolbach LL, Krant MJ. A serum alkaline phosphatase isoenzyme of human neoplastic cell origin. Cancer Res 1968; 28:150-4.
12. Maslow WC, Muensch HA, Azama F, Schneider AS. Sensitive fluorometry of heat-stable alkaline phosphatase (Regan enzyme) activity in serum from smokers and nonsmokers. Clin Chem 1983; 29:260-3.
13. Tamura K, Shibata Y, Matsuda Y, Ishida N. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res 1981; 41:3244-52.

14. Kottel RH, Hoch SO, Parsons RG, Hoch JA. Serum ribonuclease in cancer patients. Br J Cancer 1978; 38:280-6.
15. Reddi KK, Holland JF. Elevated serum ribonuclease in patients with pancreatic cancer. Proc Natl Acad Sci USA 1976; 73:230810.
16. Hogan-Ryan A, Fennelly JJ, Jones M, Cantwell B, Dubby MJ. Serum sialic acid and CEA concentrations in human breast cancer. Br J Cancer 1980; 41:587-92.
17. Lipton A, Harvey HA, Delong S, Allegra J, White D, Allegra M, et al. Glycoproteins and human cancer. I. Circulating levels in cancer serum. Cancer 1979; 43:1766-71.
18. Harvey HA, Lipton A, White D, Davidson EA. Glycoproteins and human cancer. II. Correlation between circulating level and disease status. Cancer 1981; 47:324-7.
19. Comb DC, Roseman S. Sialic acids. I. Structure and enzymatic synthesis of N-acethylneuraminic acid. J Biol Chem 1960; 235:2529-37.
20. Kobayashi T. A method for estimating the growth rate of cancer cells in vivo. Proceedings of the Fifth Annual Meeting of the Tumor Marker 1985; 1:206-8.
21. Koprowski H, Steplewski Z, Mitchell K, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybrydoma antibodies. Somat Cell Genet 1979; 5:957-72.
22. Bjorklund B. On the nature of the clinical use of Tissue-Polypeptide Antigen (TPA). Tumor Diagnostik 1980; 1:9-20.
23. Kobayashi T. Correlation between tumor markers and tumor size. Cancer Detect Prev 1987; 10:81-7.
24. Gullino PM. Natural history of breast cancer: progression from hyperplasia to neoplasia as predicted by angiogenesis. Cancer 1977; 39:2697-703.
25. Bond WH. The influence of various treatments on survival rates in cancer of breasts. In: Jarrett AS, editor. The treatment of carcinoma of the breast. Amsterdam: Amsterdam Excerpta Medica Foundation, 1968:24-39.
26. Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 1956; 76:988-1000.
27. MacDonald I. The natural history of mammary carcinoma. Am Surg 1966; 111:435-42.
28. Sugano H. Some consideration on microcancer and latent cancer. Taisha-Metabolism and Disease 1982; 19(Suppl):1193-7.
29. Hirayama T. Cancer incidence during a lifetime. In: Preventive Oncology. Tokyo: Shinjuku-Shobo, Inc., 1980; 31-6.
30. Stukonis MK. Cancer incidence cumulative rates: international comparisons based on data from "Cancer Incidence" in Five Continents". Lyon, 1978: IARC Internal Technical Report No. 78/002.
31. Pluygers EP, Beaudui MP, Baldewyns PE, Burion JA. Tumor markers for cancer detection: 11. Cancer Detect Prev 1986; 9:5059.
32. Hayashida S, Sugimoto K, Kobayashi T. The clinical effect of hyperthermia combined with induced hypertension chemotherapy. Jpn Cancer Chemother 1984; 6:1218-24.